Please login to the form below

Not currently logged in
Email:
Password:

HPP

This page shows the latest HPP news and features for those working in and with pharma, biotech and healthcare.

Alexion adds to pipeline rebuild with $855m Wilson buy

Alexion adds to pipeline rebuild with $855m Wilson buy

A $1bn purchase of Enobia in 2011 gave it an enzyme therapy for the ultra-orphan disease hypophosphatasia (HPP) - Strensiq (asfotase alfa) - which made $340m in sales last year but still

Latest news

  • NICE broadens access to Alexion's rare disease drug Strensiq NICE broadens access to Alexion's rare disease drug Strensiq

    New deal offers NHS England a discount for the drug. More babies with the rare and life-threatening disease paediatric-onset hypophosphatasia (HPP) will be able to get access to ... There are up to seven cases of HPP diagnosed every year in England, and

  • AZ, BMS and Boehringer among UK Prix Galien finalists AZ, BMS and Boehringer among UK Prix Galien finalists

    asfotase alfa. Strensiq. Alexion. paediatric-onset hypophosphatasia (HPP) - bone manifestations. Real World Evidence Award 2016 finalists.

  • Alexion's rare bone disorder therapy rejected by NICE Alexion's rare bone disorder therapy rejected by NICE

    The National Institute for Health and Care Excellence (NICE) has said evidence for the drug's benefits in paediatric-onset hypophosphatasia (HPP) - a rare, inherited disorder of the bones - is not ... pain. There are around seven cases of HPP diagnosed

  • Ten new medicines recommended in Europe Ten new medicines recommended in Europe

    David Hallal, CEO of Alexion, said: “The CHMP positive opinions for Strensiq and Kanuma are significant milestones in bringing these therapies to infants, children, and adults suffering from HPP and ... Both Strensiq and Kanuma are highly innovative

  • Alexion expands in Ireland with new biofacility Alexion expands in Ireland with new biofacility

    It is however hoping to add a second from its own stable later this year - Strensiq (asfotase alfa) for hypophosphatasia (HPP) - as well as Kanuma (sebelipase alfa) for lysosomal acid lipase

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics